Nicaise Claude — SEC Form 4 filings
SEC reporting owner CIK 1644162. 10 Form 4 filings on record with FilingPulse; latest filed 2026-07-17.
Transaction summary — filings shown
Covers all 10 filings on record, filed 2024-03-05 to 2026-07-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 2,491 shares, $248,203 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 15.
- Largest priced transaction: sale of 2,491 shares @ $99.64 ($248,203) in Sarepta Therapeutics, Inc., filed 2025-03-13.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | Director | 5 | — | 1 leg · 2,491 sh · $248,203 | 10 |
| Gain Therapeutics, Inc. (GANX) | Director | 3 | — | — | 3 |
| CASSAVA SCIENCES INC (SAVA) | Director | 2 | — | — | 2 |
Form 4 filings — Nicaise Claude
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-17 | 4 | Gain Therapeutics, Inc. (GANX) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Sarepta Therapeutics, Inc. (SRPT) | Grant/award (A): 16,875 | EDGAR |
| 2026-01-29 | 4 | Sarepta Therapeutics, Inc. (SRPT) | Option exercise (M): 10,500 @ $13.71 · Tax withholding (F): 6,780 @ $21.23 · Option exercise (M): 10,500 (derivative) @ $0 | EDGAR |
| 2025-06-25 | 4 | Gain Therapeutics, Inc. (GANX) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-05-27 | 4 | CASSAVA SCIENCES INC (SAVA) | Grant/award (A): 26,500 (derivative) @ $0 | EDGAR |
| 2025-03-13 | 4 | Sarepta Therapeutics, Inc. (SRPT) | Option exercise (M): 9,746 @ $25.18 · Sale (S): 2,491 @ $99.64 · Option exercise (M): 9,746 (derivative) @ $0 | EDGAR |
| 2025-03-11 | 4 | Sarepta Therapeutics, Inc. (SRPT) | Grant/award (A): 2,383 · Grant/award (A): 4,792 (derivative) @ $0 | EDGAR |
| 2024-06-26 | 4 | Gain Therapeutics, Inc. (GANX) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2024-05-13 | 4 | CASSAVA SCIENCES INC (SAVA) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2024-03-05 | 4 | Sarepta Therapeutics, Inc. (SRPT) | Grant/award (A): 1,846 @ $0 · Grant/award (A): 3,679 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1644162 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →